Boundless Bio to Present at the 41st Annual J.P. Morgan Healthcare Conference
Boundless Bio. a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, today announced that its Chief Executive Officer, Zachary Hornby, will present at the 41st Annual J.P. Morgan Healthcare Conference which will take place in San Francisco. Presentation details are as follows:
Date: Wednesday, January 11, 2023
Time: 8:00 – 8:25 AM PT
Location: The Westin St. Francis San Francisco
About Boundless Bio
Boundless Bio is a next-generation precision oncology company dedicated to the discovery and development of a new class of drugs targeting a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with oncogene amplified cancers.
For more information, visit www.boundlessbio.com.
Follow us on LinkedIn and Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221228005056/en/
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
